Patents by Inventor John E. Munroe

John E. Munroe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of making HIV protease inhibitors
    Patent number: 6693199
    Abstract: A method of making HIV protease inhibitors of general formula (1): These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: February 17, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Cryptophycin compounds
    Patent number: 6680311
    Abstract: The present invention provides cryptophycin compounds of Formula I that are useful in the treatment of neoplasms.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: January 20, 2004
    Assignees: Eli Lilly and Company, Wayne State University, University of Hawaii
    Inventors: Rima S Al-Awar, William J Ehlhardt, Subbaraju V Gottumukkala, Michael J Martinelli, Eric D Moher, Richard E Moore, John E Munroe, Bryan H Norman, Vinod F Patel, James E Ray, Chuan Shih, John E Toth, Venkatraghavan Vasudevan
  • Method of making HIV protease inhibitors
    Publication number: 20030216569
    Abstract: A method of making HIV protease inhibitors of general formula (1): 1
    Type: Application
    Filed: November 21, 2002
    Publication date: November 20, 2003
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 6525215
    Abstract: Compounds useful as intermediates in the preparation of HIV protease inhibitors.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: February 25, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Publication number: 20020077338
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Application
    Filed: June 21, 2001
    Publication date: June 20, 2002
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Anti-viral compounds
    Patent number: 6180815
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Anti-viral compounds
    Patent number: 6180816
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Anti-viral compounds
    Patent number: 6175034
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: January 16, 2001
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
    Patent number: 6162812
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: December 19, 2000
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • Anti-viral compounds
    Patent number: 6156924
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: December 5, 2000
    Assignee: Eli Lilly and Company
    Inventors: William J. Hornback, Scott C. Mauldin, John E. Munroe
  • Anti-viral method
    Patent number: 6127422
    Abstract: A method of inhibiting an envelope virus selected from the group consisting of influenza bovine diarrheal, hepatitis C and tick borne encephalitis virus that udergoes hemagglutinin-mediated fusion with a host cell is disclosed which comprises administering to a virus-infected cell, a cell susceptible of infection or a mammal in need thereof, an effective amount of a compound as defined by Formula I in the specification.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: October 3, 2000
    Assignee: Eli Lilly and Company
    Inventors: Joseph M. Colacino, William J. Hornback, Scott C. Mauldin, John E. Munroe, Joseph C. Tang
  • Anti-viral compounds
    Patent number: 6124494
    Abstract: The present invention provides compounds which inhibit. an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: September 26, 2000
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Anti-viral compounds
    Patent number: 6103923
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Anti-viral compounds
    Patent number: 6103922
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: William J. Hornback, John E. Munroe
  • Anti-viral compounds
    Patent number: 6100426
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: August 8, 2000
    Assignee: Eli Lilly and Company
    Inventors: Scott C. Mauldin, John E. Munroe
  • Anti-viral compounds
    Patent number: 6096917
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: August 1, 2000
    Assignee: Eli Lilly and Company
    Inventors: William J. Hornback, Scott C. Mauldin, John E. Munroe
  • Anti-viral method
    Patent number: 6060484
    Abstract: The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: May 9, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E. Fritz, Stephen W. Kaldor, Jeffrey A. Kyle, John E. Munroe
  • HIV protease inhibitors
    Patent number: 5952343
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, William J. Hornback, Stephen W. Kaldor, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 5837710
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: William J. Hornback, Vincent J. Kalish, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriguez
  • HIV protease inhibitors
    Patent number: 5834467
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 10, 1998
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Vincent J. Kalish, Bruce A. Dressman, James E. Fritz, Marlys Hammond, William J. Hornback, Stephen W. Kaldor, John E. Munroe, Siegfried Heinz Reich, John H. Tatlock, Timothy A. Shepherd, Michael J. Rodriquez